© Laboratory of Proteomics for Drug Discovery, Center for Drug Design Research, National Institutes of Biomedical Innovation, Health and Nutrition
2024年
- Sakane S, Hikita H, Shirai K, Sakamoto T, Narumi R, Adachi J, Kakita N, Yamada Y, Toyoda H, Takahashi H, Suda G, Kai M, Tahata Y, Sakamori R, Kumazaki S, Fukumoto K, Myojin Y, Kodama T, Tatsumi T, Tomonaga T, Sakamoto N, Morii E, Takehara T. Proteomic analysis of serum extracellular vesicles reveals Fibulin-3 as a new marker predicting liver-related events in MASLD. Hepatol Commun. 2024 in press.
- Muraoka S, Adachi J*. Systematic identification of kinase-substrates relationship by integrated phosphoproteome and interactome analysis. Methods Mol Biol., Proteomics for Drug Discovery. 2024 in press.
- Tozuka T, Noro R, Yoshida K, Takahashi S, Hirao M, Matsuda M, Kato Y, Nakamichi S, Takeuchi S, Matsumoto M, Miyanaga A, Kunugi S, Honda K, Adachi J, Seike M. Phosphoproteomic analysis identified mutual phosphorylation of FAK and Src as a mechanism of osimertinib resistance in EGFR-mutant lung cancer. JTO Clin Res Rep. 2024 in press.
- Tomoto M, Mineharu Y, Sato N, Tamada Y, Nogami-Itoh M, Kuroda M, Adachi J, Takeda Y, Mizuguchi K, Kumanogoh A, Natsume-Kitatani Y, Okuno Y. Idiopathic pulmonary fibrosis-specific Bayesian network integrating extracellular vesicle proteome and clinical information. Sci Rep. 14(1):1315. 2024. DOI: 10.1038/s41598-023-50905-8